北京大学学报(医学版) ›› 2016, Vol. 48 ›› Issue (4): 663-666. doi: 10.3969/j.issn.1671-167X.2016.04.019

• 论著 • 上一篇    下一篇

新疆原发性肺腺癌表皮生长因子受体基因突变与临床病理特征分析

马晓梅,曹燕珍,姬文莉,赵峰,房新志△   

  1. (新疆医科大学第三附属肿瘤医院病理科, 乌鲁木齐830011)
  • 出版日期:2016-08-18 发布日期:2016-08-18
  • 通讯作者: 房新志 E-mail:fangxinzhi2013@163.com
  • 基金资助:

    新疆维吾尔自治区自然科学基金面上项目(2014211C115)资助

Analysis of epidermal growth factor receptor mutations and its clinico-pathologic characteristics of the primary lung adenocarcinoma in Xinjiang Uighur Autonomous Region

MA Xiao-mei, CAO Yan-zhen, JI Wen-li, ZHAO Feng, FANG Xin-zhi△   

  1. (Department of Pathology, The Third Affiliated Hospital of Xinjiang Medical University, Urumqi 830011, China)
  • Online:2016-08-18 Published:2016-08-18
  • Contact: FANG Xin-zhi E-mail:fangxinzhi2013@163.com
  • Supported by:

    Supported by the Natural Science Foundation of Xinjiang Uighur Autonomous Region(2014211C115)

摘要:

目的:探讨新疆原发性肺腺癌中表皮生长因子受体(epidermal growth factor receptor, EGFR)基因突变情况及与临床病理特征的关系。方法:采用扩增阻滞突变系统(amplification refractory mutation system,ARMS)荧光PCR法对59 例(维吾尔族15例,汉族44例)新疆维吾尔族及汉族原发性肺腺癌手术切除标本进行EGFR基因第18-21号外显子的突变检测,同时分析其与患者临床病理特征的关系。结果:在新疆地区原发性肺腺癌手术切除标本患者中,EGFR基因突变率维吾尔族低于汉族,分别为20%(3/15)和54.5%(24/44),差异具有统计意义(P<0.05);其中EGFR外显子19缺失突变维吾尔族2例,汉族9例,外显子21L858R突变维吾尔族1例,汉族12例,外显子18G719X突变汉族2例,外显子21L861Q突变汉族1例。在病理组织学类型上,腺泡状为主型腺癌EGFR突变率为71%(22/31),高于实性为主型EGFR突变率6.7%(1/15)和黏液腺癌EGFR突变率20%(1/5)。EGFR基因突变与维吾尔族或汉族肺腺癌患者的性别、年龄、部位、大体类型、淋巴结转移情况、吸烟指数及临床分期等差异无统计学意义(P>0.05)。结论:新疆原发性肺腺癌EGFR基因突变率在维吾尔族与汉族有不同,可能反映民族遗传差异性,值得进一步研究。EGFR基因突变常见于高中分化腺癌,或以腺泡状为主型多见。

关键词: 肺腺癌, 受体, 表皮生长因子, 突变, 聚合酶链反应

Abstract:

Objective:To clarify the relationship between epidermal growth factor receptor (EGFR) mutations and the clinicopathologic features of primary lung adenocarcinomas in Xinjiang. Methods: The mutations of EGFR gene at exons 18-21 in 59 cases (including 15 cases of Uighur and 44 cases of Han) of lung adenocarcinoma tissues, which were obtained from surgical resection, were detected by amplification refractory mutation system (ARMS) method. And the relationships among mutations, race and clinicopathologic features were analyzed.Results: The frequencies of EGFR mutations in lung adenocarcinoma were 20% for Uighur, which was lower than that in Han (54.5%), P<0.05. The deletion mutations at exon 19 were seen in 2 of 15 Uighur cases and 9 of 44 Han cases. EGFR mutations were present, including exon 21 L858R in one Uighur case and 12 Han cases, exon 18 G719X in two of 44 cases of Han, exon 21 L861Q in one of them. On histological type, the frequencies of EGFR mutation in alveolar predominant adenocarcinoma was 71% (22/31), which was higher than both that in solid predominant and mucinous carcinoma ( 6.7%, 20% respectively). According to statistic analysis, EGFR mutations were without correlation with the patient’s gender, age, location, gross type, smoking status and lymph node metastasis(P>0.05). EGFR mutation was more frequent in well-differentiated cancer, mainly in acinar carcinoma, while poorly differentiated adenocarcinoma and mucous adenocarcinoma were lower. Conclusion: There was a difference of EGFR mutation in primary lung adenocarcinoma between Uighur and Han in Xinjiang, perhaps reflecting ethnic genetic variation, which is worth further analyzing. EGFR mutation was commonly detected in well or middle differentiated adenocarcinoma, mainly in acinar carcinoma.

Key words: Adenocarcinoma of lung, Receptor, epidermal growth factor, Mutation, Polymerase chain reaction

中图分类号: 

  • R734.2
[1] 汤莹, 张湧波, 吴丹红, 林炎鸿, 兰风华. 13例先天性双侧输精管缺如不育患者的致病基因突变检测[J]. 北京大学学报(医学版), 2024, 56(5): 763-774.
[2] 扶琼,叶霜. 嵌合抗原受体T细胞治疗在自身免疫疾病中的应用和思考[J]. 北京大学学报(医学版), 2023, 55(6): 953-957.
[3] 时云飞,王豪杰,刘卫平,米岚,龙孟平,刘雁飞,赖玉梅,周立新,刁新婷,李向红. 血管免疫母细胞性T细胞淋巴瘤临床与分子病理学特征分析[J]. 北京大学学报(医学版), 2023, 55(3): 521-529.
[4] 朱晓娟,张虹,张爽,李东,李鑫,徐玲,李挺. 人表皮生长因子受体2低表达乳腺癌的临床病理学特征及预后[J]. 北京大学学报(医学版), 2023, 55(2): 243-253.
[5] 熊焰,张波,聂立功,吴世凯,赵虎,李东,邸吉廷. 胸部SMARCA4缺失性未分化肿瘤的病理诊断与联合免疫检测点抑制剂治疗[J]. 北京大学学报(医学版), 2023, 55(2): 351-356.
[6] 周秋君,龚潘,焦莶如,杨志仙. 1例Angelman综合征合并眼皮肤白化病2型患者的临床和遗传学分析及文献回顾[J]. 北京大学学报(医学版), 2023, 55(1): 181-185.
[7] 程昉,杨邵英,房星星,王璇,赵福涛. CCL28-CCR10通路在类风湿关节炎单核细胞迁移中的作用[J]. 北京大学学报(医学版), 2022, 54(6): 1074-1078.
[8] 董尔丹. 心血管受体的信号转导与疾病[J]. 北京大学学报(医学版), 2022, 54(5): 796-802.
[9] 王跃,张爽,张虹,梁丽,徐玲,程元甲,段学宁,刘荫华,李挺. 激素受体阳性/人表皮生长因子受体2阴性乳腺癌临床病理特征及预后[J]. 北京大学学报(医学版), 2022, 54(5): 853-862.
[10] 程晓静,蒋栋,张连海,王江华,李雅真,翟佳慧,闫宝琪,张露露,谢兴旺,李子禹,季加孚. KRAS G12V特异性T细胞受体治疗恶性肿瘤的临床前研究[J]. 北京大学学报(医学版), 2022, 54(5): 884-895.
[11] 李芷晴,俞冰,蔡泽宇,王迎宝,张煦,周彪,方晓红,于芳,付毅,孙金鹏,李伟,孔炜. 柚皮素抑制马凡综合征小鼠胸主动脉瘤的形成[J]. 北京大学学报(医学版), 2022, 54(5): 896-906.
[12] 蔡天玉,朱振鹏,徐纯如,吉星,吕同德,郭振可,林健. 成纤维细胞生长因子受体2在肾透明细胞癌中的表达及意义[J]. 北京大学学报(医学版), 2022, 54(4): 628-635.
[13] 秦彩朋,宋宇轩,丁梦婷,王飞,林佳兴,杨文博,杜依青,李清,刘士军,徐涛. 肾癌免疫治疗疗效评估突变预测模型的建立[J]. 北京大学学报(医学版), 2022, 54(4): 663-668.
[14] 陈曦,王斯悦,薛恩慈,王雪珩,彭和香,范梦,王梦莹,武轶群,秦雪英,李劲,吴涛,朱洪平,李静,周治波,陈大方,胡永华. 基于核心家系全外显子组测序数据探索新生突变与非综合征型唇腭裂的关联[J]. 北京大学学报(医学版), 2022, 54(3): 387-393.
[15] 顾阳春,刘颖,谢超,曹宝山. 程序性死亡蛋白-1抑制剂治疗晚期肺癌出现垂体免疫不良反应3例[J]. 北京大学学报(医学版), 2022, 54(2): 369-375.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
No Suggested Reading articles found!